Please use this identifier to cite or link to this item: http://hdl.handle.net/10773/40052
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLaranjeira, Paulapt_PT
dc.contributor.authorPedrosa, Móniapt_PT
dc.contributor.authorDuarte, Cátiapt_PT
dc.contributor.authorPedreiro, Susanapt_PT
dc.contributor.authorAntunes, Brígidapt_PT
dc.contributor.authorRibeiro, Tâniapt_PT
dc.contributor.authorDos Santos, Franciscopt_PT
dc.contributor.authorMartinho, Antóniopt_PT
dc.contributor.authorFardilha, Margaridapt_PT
dc.contributor.authorDomingues, M Rosáriopt_PT
dc.contributor.authorAbecasis, Manuelpt_PT
dc.contributor.authorPereira da Silva, José Antóniopt_PT
dc.contributor.authorPaiva, Arturpt_PT
dc.date.accessioned2024-01-10T16:38:38Z-
dc.date.available2024-01-10T16:38:38Z-
dc.date.issued2022-02-12-
dc.identifier.issn1999-4923pt_PT
dc.identifier.urihttp://hdl.handle.net/10773/40052-
dc.description.abstractRheumatoid arthritis (RA) is a disabling autoimmune disease whose treatment is ineffective for one-third of patients. Thus, the immunomodulatory potential of mesenchymal stromal/stem cells (MSCs) makes MSC-based therapy a promising approach to RA. This study aimed to explore the immunomodulatory action of human bone marrow (BM)-MSCs on myeloid dendritic cells (mDCs) and monocytes, especially on cytokines/chemokines involved in RA physiopathology. For that, LPS plus IFNγ-stimulated peripheral blood mononuclear cells from RA patients (n = 12) and healthy individuals (n = 6) were co-cultured with allogeneic BM-MSCs. TNF-α, CD83, CCR7 and MIP-1β protein levels were assessed in mDCs, classical, intermediate, and non-classical monocytes. mRNA expression of other cytokines/chemokines was also evaluated. BM-MSCs effectively reduced TNF-α, CD83, CCR7 and MIP-1β protein levels in mDCs and all monocyte subsets, in RA patients. The inhibition of TNF-α production was mainly achieved by the reduction of the percentage of cellsproducing this cytokine. BM-MSCs exhibited a remarkable suppressive action over antigen-presenting cells from RA patients, potentially affecting their ability to stimulate the immune adaptive response at different levels, by hampering their migration to the lymph node and the production of proinflammatory cytokines and chemokines. Accordingly, MSC-based therapies can be a valuable approach for RA treatment, especially for non-responder patients.pt_PT
dc.language.isoengpt_PT
dc.publisherMDPIpt_PT
dc.rightsopenAccesspt_PT
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/pt_PT
dc.titleHuman Bone Marrow Mesenchymal Stromal/Stem Cells Regulate the Proinflammatory Response of Monocytes and Myeloid Dendritic Cells from Patients with Rheumatoid Arthritispt_PT
dc.typearticlept_PT
dc.description.versionpublishedpt_PT
dc.peerreviewedyespt_PT
degois.publication.issue2pt_PT
degois.publication.titlePharmaceuticspt_PT
degois.publication.volume14pt_PT
dc.identifier.doi10.3390/pharmaceutics14020404pt_PT
dc.identifier.articlenumber404pt_PT
Appears in Collections:CBC - Artigos
CESAM - Artigos
IBIMED - Artigos
DCM - Artigos
REQUIMTE - Artigos

Files in This Item:
File Description SizeFormat 
pharmaceutics-14-00404.pdf3.86 MBAdobe PDFView/Open


FacebookTwitterLinkedIn
Formato BibTex MendeleyEndnote Degois 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.